This is a contrast between INSYS Therapeutics Inc. (NASDAQ:INSY) and Intec Pharma Ltd. (NASDAQ:NTEC) based on their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 represents INSYS Therapeutics Inc. (NASDAQ:INSY) and Intec Pharma Ltd. (NASDAQ:NTEC)’s net margins, return on equity and return on assets.
INSYS Therapeutics Inc. and Intec Pharma Ltd. Recommendations and Ratings are available in the next table.
INSYS Therapeutics Inc.’s average target price is $7.75, while its potential upside is 69.21%.
Insider Institutional Ownership
The shares of both INSYS Therapeutics Inc. and Intec Pharma Ltd. are owned by institutional investors at 18.9% and 39.64% respectively. INSYS Therapeutics Inc.’s